Clinical Trial

Aditxt, Inc. Announces Appointment of Ernie Lee as CEO of its Wholly-Owned Subsidiary, Pearsanta, to Lead Launch of Test2Treat.me Platform

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc., (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation activation company focused on the discovery,…

1 year ago

COSMOS HEALTH CEO Issues Letter to Shareholders

Company reaches major strategic inflection point, with operations and revenue ramp-up underway, to significantly accelerate in 2024 and beyondMaintains solid…

1 year ago

Zomedica Announces Acquisition of TRUFORMA Platform Developer Qorvo Biotech LLC, Accelerating Timeline to Gain Control of Manufacturing and Research & Development

ANN ARBOR, MI / ACCESSWIRE / October 5, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary…

1 year ago

H1 Boosts Flagship Clinical Trial Intelligence Platform with Generative AI to Accelerate Clinical Trials

Seamlessly nestled within Trial Landscape, GenosAI™ enables pharma to look across vast data sets, simplify complex queries, and accelerate clinical…

1 year ago

Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

COPENHAGEN, Denmark, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology…

1 year ago

SeaStar Medical to Present at the Dawson James Small Cap Growth Conference on October 12, 2023

DENVER, Oct. 05, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions…

1 year ago

Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™

– Resubmission follows the satisfactory resolution of the FDA’s review of inspection findings at the third-party filler – REDWOOD CITY, Calif.,…

1 year ago

Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

TN-201 is the First Gene Therapy for the Leading Genetic Cause of HCM to be Assessed in Humans; Adds Working…

1 year ago